Nektar Therapeutics (NKTR) Company Profile & Statistics

Nektar Therapeutics
NKTR
(Nasdaq - US)
N/A
1.32
+0.00 (0.00%)
in:usd•As of: Apr 26, 2024 15:59 UTC -4
Open
1.33
High
1.37
Low
1.32

About Nektar Therapeutics

CEO

Howard W. Robin

Headquarters

455 mission bay boulevard south

san francisco, ca 94158, united states

Auditor

Ernst & Young LLP

Employees

137

Share Holders

145

Website

www.nektar.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.

Nektar Therapeutics Statistics

Valuation Measures

Market Capitalization ²	242.38M
Enterprise Value	207.10M
Enterprise Value/EBITDA (ttm)	-1.15
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.92
Price to Sales (ttm)	2.69
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	62.80%
Operating Margin (ttm)	-195.53%
Profit Margin (ttm)	-312.48%
Return on Equity (ttm)	-96.80%
Return on Invested Capital (ttm)	-143.73%
Return on Assets (ttm)	-37.17%

Income Statement

Revenue (ttm)	90.12M
Revenue Per Share (ttm)	0.49
Gross Profit (ttm)	56.35M
EBITDA (ttm)³	-179.37M
Net Income Avi to Common (ttm)	-276.06M
Diluted EPS (ttm)	-1.46

Share Statistics

Beta (5Y Monthly)	0.90
52-Week Change	70.65%
S&P500 52-Week Change	25.74%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	183.62M
Dividend Yield	0.00%
Float ⁴	177.98M
% Held by Insiders	3.07%
% Held by Institutions	75.88%

Balance Sheet

Total Cash (mrq)	303.62M
Total Cash Per Share (mrq)	1.65
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	6.45%
Quick Ratio (mrq)	6.14%
Book Value Per Share (mrq)	0.68

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.01
Free Cash Flow (ytd)	-192.23M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Nektar Therapeutics

Trade With A Regulated Broker